top of page
May 18

SEAVI Advent Announces Investment in Leading TCM Provider, Shuang Yi Pharmaceutical and Biotech Holdings

May 2026 SEAVI Advent Private Equity today announced that its latest fund, SEAVI Advent VIII Fund has completed an investment in Shuang Yi Pharmaceutical and Biotech Holdings Ltd (the "Company"). The Company is a national high-tech enterprise specializing in the R&D, biotechnological extraction, standardization, and commercialization of Zhuang traditional medicines and botanical drug candidates. The Company has repeatedly been recognized as a National High-tech Enterprise and

May 18

SEAVI Advent Private Equity announces the 1st close of its latest fund - SEAVI Advent Equity VIII

May 2026 SEAVI Advent Private Equity has announced the 1st closing of its latest fund - SEAVI Advent Equity VIII, consisting of 2 sub-funds under its SEAVI Advent VCC. The Fund's initial close was raised from high net-worth individuals, corporate institutions and family offices. SEAVI Advent's partners also made a strong commitment of US$3 million in the Fund. SEAVI Advent will continue to reach out to existing and new investors, mostly based in Singapore, Hong Kong, Mainland

May 14

SEAVI Advent Private Equity announces that it has fully exited its holdings in Xuan Wu Cloud Technology Holding

SEAVI Advent Private Equity today announced that it has fully exited its holdings in Xuan Wu Cloud Technology Holding (Stock Code: 02392.HK), a leading intelligent Customer Relationship Management SaaS company focused on serving mid and large-cap enterprise customers in the People’s Republic of China. SEAVI Advent’s investment in Xuan Wu during the Covid-19 period supported the company’s capital markets strategy and helped in its international expansion into Southeast Asia,

Feb 11

SEAVI Advent Announces Paring Down of its Investment in Huitongda Network Co., Ltd

10 February 2026 SEAVI Advent Private Equity today announced that it has pared down its holdings in Huitongda Network Co., Ltd (Stock Code: 9878.HK) (the “Company”) to residual value so as to address overhang issues of the Company. While SEAVI has realised a portion of its position, it retains a sizable stake in the Company, reflecting a continued commitment to capturing the Company’s full intrinsic value as capital market conditions evolve. The Company has demonstrated robus

bottom of page